CytomX Therapeutics announced that the Phase 1 trial of its ADC candidate, CX-2051, in colorectal cancer will continue. This decision was made by a safety committee following a patient death in the study.
The company did not provide specific details regarding the patient death. However, the continuation of the trial indicates that the safety committee determined it was appropriate to proceed with the study.
The decision allows for the ongoing evaluation of CX-2051, a key program for CytomX, in patients with colorectal cancer. The company's commitment to patient safety remains paramount as the trial progresses.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.